Literature DB >> 30530594

The mTORC1/4E-BP/eIF4E Axis Promotes Antibody Class Switching in B Lymphocytes.

Honyin Chiu1, Leandra V Jackson1, Kwon Ik Oh1,2, Annie Mai1, Ze'ev A Ronai3, Davide Ruggero4,5, David A Fruman6.   

Abstract

During an adaptive immune response, activated mature B cells give rise to Ab-secreting plasma cells to fight infection. B cells undergo Ab class switching to produce different classes of Abs with varying effector functions. The mammalian/mechanistic target of rapamycin (mTOR) signaling pathway is activated during this process, and disrupting mTOR complex 1 (mTORC1) in B cells impairs class switching by a poorly understood mechanism. In particular, it is unclear which mTORC1 downstream substrates control this process. In this study, we used an in vitro murine model in which the mTORC1 inhibitor rapamycin, when added after a B cell has committed to divide, suppresses class switching while preserving proliferation. Investigation of mTORC1 substrates revealed a role for eukaryotic translation initiation factor 4E (eIF4E) and eIF4E-binding proteins in class switching. Mechanistically, we show that genetic or pharmacological disruption of eIF4E binding to eIF4G reduced cap-dependent translation, which specifically affected the expression of activation-induced cytidine deaminase protein but not Aicda mRNA. This translational impairment decreased Ab class switching independently of proliferation. These results uncover a previously undescribed role for mTORC1 and the eIF4E-binding proteins/eIF4E axis in activation-induced cytidine deaminase protein expression and Ab class switching in mouse B cells, suggesting that cap-dependent translation regulates key steps in B cell differentiation.
Copyright © 2019 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30530594      PMCID: PMC6324996          DOI: 10.4049/jimmunol.1800602

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  46 in total

1.  Enhanced IgA class switching in marginal zone and B1 B cells relative to follicular/B2 B cells.

Authors:  Denise A Kaminski; Janet Stavnezer
Journal:  J Immunol       Date:  2006-11-01       Impact factor: 5.422

2.  Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E.

Authors:  Andrew C Hsieh; Maria Costa; Ornella Zollo; Cole Davis; Morris E Feldman; Joseph R Testa; Oded Meyuhas; Kevan M Shokat; Davide Ruggero
Journal:  Cancer Cell       Date:  2010-03-16       Impact factor: 31.743

Review 3.  Targeting the eIF4F translation initiation complex: a critical nexus for cancer development.

Authors:  Jerry Pelletier; Jeremy Graff; Davide Ruggero; Nahum Sonenberg
Journal:  Cancer Res       Date:  2015-01-15       Impact factor: 12.701

4.  Regulation of class-switch recombination and plasma cell differentiation by phosphatidylinositol 3-kinase signaling.

Authors:  Sidne A Omori; Matthew H Cato; Amy Anzelon-Mills; Kamal D Puri; Miriam Shapiro-Shelef; Kathryn Calame; Robert C Rickert
Journal:  Immunity       Date:  2006-09-28       Impact factor: 31.745

Review 5.  Molecular Pathways: The eIF4F Translation Initiation Complex-New Opportunities for Cancer Treatment.

Authors:  Hélène Malka-Mahieu; Michelle Newman; Laurent Désaubry; Caroline Robert; Stéphan Vagner
Journal:  Clin Cancer Res       Date:  2016-10-27       Impact factor: 12.531

6.  Failure of rapamycin to block proliferation once resting cells have entered the cell cycle despite inactivation of p70 S6 kinase.

Authors:  N Terada; R A Franklin; J J Lucas; J Blenis; E W Gelfand
Journal:  J Biol Chem       Date:  1993-06-05       Impact factor: 5.157

7.  Inhibition of the immune response by rapamycin, a new antifungal antibiotic.

Authors:  R R Martel; J Klicius; S Galet
Journal:  Can J Physiol Pharmacol       Date:  1977-02       Impact factor: 2.273

8.  eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies.

Authors:  Lise Boussemart; Hélène Malka-Mahieu; Isabelle Girault; Delphine Allard; Oskar Hemmingsson; Gorana Tomasic; Marina Thomas; Christine Basmadjian; Nigel Ribeiro; Frédéric Thuaud; Christina Mateus; Emilie Routier; Nyam Kamsu-Kom; Sandrine Agoussi; Alexander M Eggermont; Laurent Désaubry; Caroline Robert; Stéphan Vagner
Journal:  Nature       Date:  2014-07-27       Impact factor: 49.962

9.  A unifying model for mTORC1-mediated regulation of mRNA translation.

Authors:  Carson C Thoreen; Lynne Chantranupong; Heather R Keys; Tim Wang; Nathanael S Gray; David M Sabatini
Journal:  Nature       Date:  2012-05-02       Impact factor: 49.962

10.  nanoCAGE reveals 5' UTR features that define specific modes of translation of functionally related MTOR-sensitive mRNAs.

Authors:  Valentina Gandin; Laia Masvidal; Laura Hulea; Simon-Pierre Gravel; Marie Cargnello; Shannon McLaughlan; Yutian Cai; Preetika Balanathan; Masahiro Morita; Arjuna Rajakumar; Luc Furic; Michael Pollak; John A Porco; Julie St-Pierre; Jerry Pelletier; Ola Larsson; Ivan Topisirovic
Journal:  Genome Res       Date:  2016-03-16       Impact factor: 9.043

View more
  8 in total

Review 1.  Cell type-specific mechanistic target of rapamycin-dependent distortion of autophagy pathways in lupus nephritis.

Authors:  Tiffany Caza; Chathura Wijewardena; Laith Al-Rabadi; Andras Perl
Journal:  Transl Res       Date:  2022-03-12       Impact factor: 10.171

Review 2.  Regulation and metabolic functions of mTORC1 and mTORC2.

Authors:  Angelia Szwed; Eugene Kim; Estela Jacinto
Journal:  Physiol Rev       Date:  2021-02-18       Impact factor: 46.500

3.  Krüppel-like factor 2 controls IgA plasma cell compartmentalization and IgA responses.

Authors:  Jens Wittner; Sebastian R Schulz; Tobit D Steinmetz; Johannes Berges; Manuela Hauke; William M Channell; Adam F Cunningham; Anja E Hauser; Andreas Hutloff; Dirk Mielenz; Hans-Martin Jäck; Wolfgang Schuh
Journal:  Mucosal Immunol       Date:  2022-03-28       Impact factor: 8.701

4.  Antigen Complexed with a TLR9 Agonist Bolsters c-Myc and mTORC1 Activity in Germinal Center B Lymphocytes.

Authors:  Eric J Wigton; Anthony L DeFranco; K Mark Ansel
Journal:  Immunohorizons       Date:  2019-08-19

5.  Targeting eIF4F translation initiation complex with SBI-756 sensitises B lymphoma cells to venetoclax.

Authors:  Lee-Or Herzog; Beth Walters; Roberta Buono; J Scott Lee; Sharmila Mallya; Amos Fung; Honyin Chiu; Nancy Nguyen; Boyang Li; Anthony B Pinkerton; Michael R Jackson; Robert J Schneider; Ze'ev A Ronai; David A Fruman
Journal:  Br J Cancer       Date:  2020-12-14       Impact factor: 7.640

6.  HIV-1 Tat Activates Akt/mTORC1 Pathway and AICDA Expression by Downregulating Its Transcriptional Inhibitors in B Cells.

Authors:  Burkitkan Akbay; Diego Germini; Amangeldy K Bissenbaev; Yana R Musinova; Evgeny V Sheval; Yegor Vassetzky; Svetlana Dokudovskaya
Journal:  Int J Mol Sci       Date:  2021-02-04       Impact factor: 5.923

Review 7.  Supplying the trip to antibody production-nutrients, signaling, and the programming of cellular metabolism in the mature B lineage.

Authors:  Mark R Boothby; Shawna K Brookens; Ariel L Raybuck; Sung Hoon Cho
Journal:  Cell Mol Immunol       Date:  2021-11-15       Impact factor: 22.096

8.  Reduced eIF4E function impairs B-cell leukemia without altering normal B-lymphocyte function.

Authors:  Honyin Chiu; Roberta Buono; Leandra V Jackson; Lee-Or Herzog; Sharmila Mallya; Crystal S Conn; Davide Ruggero; David A Fruman
Journal:  iScience       Date:  2021-06-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.